RT Journal Article
ID 0b289da5695993e1
A1 Pathak, Kamla
A1 Keshri, Lav
A1 Shah, Mayank 
T1 Lipid Nanocarriers: Influence of Lipids on Product Development and Pharmacokinetics
JF Critical Reviews™ in Therapeutic Drug Carrier Systems
JO CRT
YR 2011
FD 2011-07-25
VO 28
IS 4
SP 357
OP 393
K1 solid lipid nanoparticles
K1 SLN
K1 nanostructured lipid carriers
K1 NLC
K1 pharmacosomes
K1 lipid drug conjugates
K1 LDC
K1 product development
K1 pharmacokinetics
AB Lipid nanocarriers are on the forefront of the rapidly developing field of nanotechnology with several potential applications in drug delivery. Owing to their size-dependent properties, lipid nanoparticles offer the possibility for development of new therapeutics and an alternative system to other colloidal counterparts for drug administration. An important point to be considered in the selection of a lipid for the carrier system is its effect on the properties of the nanocarrier and also its intended use, as different types of lipids differ in their nature. Researchers around the globe have tapped the potential of solid lipid nanoparticles (SLNs) in developing formulation(s) that can be administered by various routes such as oral, ocular, parenteral, topical, and pulmonary. Since the start of this millennium, a new generation of lipid nanoparticles, namely nanostructured lipid carriers (NLCs), lipid drug conjugates (LDCs), and pharmacosomes, has evolved that have the potential to overcome the limitations of SLNs. The current review article presents broad considerations on the influence of various types of lipids on the diverse characteristics of nanocarriers, encompassing their  physicochemical, formulation, pharmacokinetic, and cytotoxic aspects.
PB Begell House
LK https://www.dl.begellhouse.com/journals/3667c4ae6e8fd136,1d024ddb05b23c57,0b289da5695993e1.html